Home > > > > > Report Detail

Diabetic Gastroparesis (DGp) - Market Insights, Epidemiology and Market Forecast-2030

Publisher Name :
Date: 15-Apr-2020
No. of pages: 139
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's ‘Diabetic Gastroparesis (DGp) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of DGp in the 7 Major Markets (MM) ,i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Diabetic Gastroparesis (DGp) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

- The United States

- EU5 (Germany, France, Italy, Spain and the United Kingdom)

- Japan

Study Period: 2017-2030

Diabetic Gastroparesis (DGp) - Disease Understanding

The term diabetic gastroparesis (DGp) has been used to describe a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. Symptoms associated with diabetic gastroparesis are early satiety, prolonged fullness, bloating, nausea and vomiting, and abdominal discomfort and pain. These symptoms are vague and nonspecific.

The DelveInsight Diabetic Gastroparesis (DGp) market report gives the thorough understanding of the Diabetic Gastroparesis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms for Diabetic Gastroparesis in the 7MM.

Diabetic Gastroparesis Epidemiology

The Diabetic Gastroparesis (DGp) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven countries in the report. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases of Diabetic Gastroparesis, prevalence of Gastroparesis associated with types of Diabetes Mellitus, prevalence of Diabetic Gastroparesis based on gender, prevalence of symptoms associated with Diabetic Gastroparesis) scenario of Diabetic Gastroparesis (DGp) in the 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017-2030.

According to DelveInsight, Total prevalent population of Diabetic Gastroparesis in 7 EM was observed to be 12,843,848 cases in 2017.

Diabetic Gastroparesis Drug Chapters

This segment of the Diabetic Gastroparesis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs along with other potential therapeutic candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The treatment landscape of DGp comprises of very few pharmacotherapies. The usual treatments for DGp include nutritional assessment and dietary modifications, glycemic control, prokinetic agents and antiemetic agents. The first line of management is focused on optimization of glycemic control known as dietary therapy in addition with the prokinetic therapy in order to improve gastric emptying and gastroparesis symptoms.

Diabetic Gastroparesis Market Outlook

The Diabetic Gastroparesis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Diabetic Gastroparesis in 7MM was found to be USD 1339.70 Million in 2017, and is expected to increase during the course of the study period (2017-2030). US accounts for the largest market size of Sickle Cell Disease, in comparison to the other 7 Major Markets i.e., United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Diabetic Gastroparesis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Diabetic Gastroparesis Report Insights

- Patient Population

- Therapeutic Approaches

- Pipeline Analysis

- Market Size and Trends

- Market Opportunities

- Impact of upcoming Therapies

Diabetic Gastroparesis Report Key Strengths

- 11 Years Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Key Cross Competition

- Market Size by Therapies

- Drugs Uptake

Diabetic Gastroparesis Report Assessment

- Pipeline Product Profiles

- Key Products and Key Players

- Market Drivers and Barriers

Key Benefits

- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Diabetic Gastroparesis market

- Organize sales and marketing efforts by identifying the best opportunities for Diabetic Gastroparesis market

- To understand the future market competition in the Diabetic Gastroparesis market.

Diabetic Gastroparesis (DGp) - Market Insights, Epidemiology and Market Forecast-2030

Table of Contents

1. Key Insights
2. Executive Summary
3. SWOT Analysis for Diabetic Gastroparesis (DGp)
4. Diabetic Gastroparesis Market Overview at a Glance
4.1. Market Share (%) Distribution of Diabetic Gastroparesis in 2017
4.2. Market Share (%) Distribution of Diabetic Gastroparesis in 2030
5. Disease Background and Overview
5.1. Introduction
5.2. Etiology and risk factors
5.3. Signs and Symptoms
5.4. Pathogenesis of Diabetic Gastroparesis
5.5. Diagnosis
5.5.1. Clinical Scoring System
5.5.2. Differential diagnosis of Diabetic Gastroparesis
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Prevalent Patient Population of Diabetic Gastroparesis
7. Country Wise-Epidemiology of Diabetic Gastroparesis
7.1. The United States
7.1.1. Assumptions and Rationale
7.1.2. Total Prevalent Cases of Diabetic Gastroparesis in the United States
7.1.3. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the United States
7.1.4. Prevalence of Diabetic Gastroparesis based on Gender in the United States
7.1.5. Prevalence of Symptoms associated with DGp in the United States
7.2. EU5
7.2.1. Assumptions and Rationale
7.3. Germany
7.3.1. Total Prevalent Cases of Diabetic Gastroparesis in Germany
7.3.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany
7.3.3. Prevalence of Diabetic Gastroparesis based on Gender in Germany
7.3.4. Prevalence of Symptoms associated with DGp in Germany
7.4. France
7.4.1. Total Prevalent Cases of Diabetic Gastroparesis in France
7.4.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France
7.4.3. Prevalence of Diabetic Gastroparesis based on Gender in France
7.4.4. Prevalence of Symptoms associated with DGp in France
7.5. Italy
7.5.1. Total Prevalent Cases of Diabetic Gastroparesis in Italy
7.5.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy
7.5.3. Prevalence of Diabetic Gastroparesis based on Gender in Italy
7.5.4. Prevalence of Symptoms associated with DGp in Italy
7.6. Spain
7.6.1. Total Prevalent Cases of Diabetic Gastroparesis in Spain
7.6.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain
7.6.3. Prevalence of Diabetic Gastroparesis based on Gender in Spain
7.6.4. Prevalence of Symptoms associated with DGp in Spain
7.7. The United Kingdom
7.7.1. Total Prevalent Cases of Diabetic Gastroparesis in the UK
7.7.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK
7.7.3. Prevalence of Diabetic Gastroparesis based on Gender in the UK
7.7.4. Prevalence of Symptoms associated with DGp in the UK
7.8. Japan
7.8.1. Assumptions and Rationale
7.8.2. Total Prevalent Cases of Diabetic Gastroparesis in Japan
7.8.3. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan
7.8.4. Prevalence of Diabetic Gastroparesis based on Gender in Japan
7.8.5. Prevalence of Symptoms associated with DGp in Japan
8. Treatment and Management of Diabetic Gastroparesis
8.1. Consensus guidelines for the clinical management of diabetic gastroparesis
8.2. Algorithm for the management of diabetic gastroparesis
8.3. Patient Journey for Diabetic Gastroparesis
9. Case study for Diabetic Gastroparesis
10. Unmet Needs
11. Marketed Drugs
11.1. Metoclopramide: ANI Pharmaceuticals, Inc
11.1.1. Drug Description
11.1.2. Regulatory Milestones
11.1.3. Other Development Activities
11.1.4. Safety and Efficacy
12. Emerging Therapies
12.1. Relamorelin: Allergan
12.1.1. Product Description
12.1.2. Other Development Activities
12.1.3. Clinical Development
12.1.4. Safety and Efficacy
12.2. Metoclopramide Nasal Spray (Gimoti): Evoke Pharma Inc.
12.2.1. Product Description
12.2.2. Other Development Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.3. Velusetrag: Theravance Biopharma
12.3.1. Product Description
12.3.2. Other Development Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.4. Sepiapterin (CNSA-001): Censa Pharmaceuticals
12.4.1. Product Description
12.4.2. Clinical Development
12.5. CIN-102: CinDome Pharma
12.5.1. Product Description
12.5.2. Clinical Development
12.5.3. Safety and Efficacy
13. Other products of interest
13.1. TAK-954: Takeda (Millennium Pharmaceuticals, Inc.)
13.1.1. Product Description
13.1.2. Other Development Activities
13.1.3. Clinical Development
13.2. TAK-906: Takeda (Millennium Pharmaceuticals, Inc.)
13.2.1. Product Description
13.2.2. Other Development Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.3. Nimacimab: Bird Rock Bio
13.3.1. Product Description
13.3.2. Other Development Activities
13.3.3. Clinical Development
14. Diabetic Gastroparesis: 7 Major Market Analysis
14.1. Key Findings
14.2. Market Size of Diabetic Gastroparesis in 7MM
14.2.1. Market Size of Diabetic Gastroparesis by Therapies
15. Market Outlook by Country
15.1. United States: Market Outlook
15.2. The United States Market Size
15.2.1. Total Market Size of Diabetic Gastroparesis
15.2.2. Market Size of Diabetic Gastroparesis by Therapies
16. EU-5 Countries: Market Outlook
16.1. Germany
16.1.1. Total Market size of Diabetic Gastroparesis
16.1.2. Market Size of Diabetic Gastroparesis by Therapies
16.2. France
16.2.1. Total Market Size of Diabetic Gastroparesis
16.2.2. Market Size of Diabetic Gastroparesis by Therapies
16.3. Italy
16.3.1. Total Market Size of Diabetic Gastroparesis
16.3.2. Market Size of Diabetic Gastroparesis by Therapies
16.4. Spain
16.4.1. Total Market Size of Diabetic Gastroparesis
16.4.2. Market Size of Diabetic Gastroparesis by Therapies
16.5. The United Kingdom
16.5.1. Total Market Size of Diabetic Gastroparesis
16.5.2. Market Size of Diabetic Gastroparesis by Therapies
17. Japan: Market Outlook
17.1. Total Market Size of Diabetic Gastroparesis
17.2. Market Size of Diabetic Gastroparesis by Therapies
18. Market Access and Reimbursement Overview of DGp
19. Market Drivers
20. Market Barriers
21. Appendix
21.1. Bibliography
21.2. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight

List of Tables

Table 1: Prevalent Patient Population of Diabetic Gastroparesis in 7MM (2017-2030)
Table 2: Total Prevalent Cases of Diabetic Gastroparesis in the United States (2017-2030)
Table 3: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the US (2017-2030)
Table 4: Prevalence of Diabetic Gastroparesis based on Gender in the United States (2017-2030)
Table 5: Prevalence of Symptoms associated with DGp in the United States (2017-2030)
Table 6: Total Prevalent Cases of Diabetic Gastroparesis in Germany (2017-2030)
Table 7: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany (2017-2030)
Table 8: Prevalence of Diabetic Gastroparesis based on Gender in Germany (2017-2030)
Table 9: Prevalence of Symptoms associated with DGp in the Germany (2017-2030)
Table 10: Total Prevalent Cases of Diabetic Gastroparesis in France (2017-2030)
Table 11: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France (2017-2030)
Table 12: Prevalence of Diabetic Gastroparesis based on Gender in France (2017-2030)
Table 13: Prevalence of Symptoms associated with DGp in France (2017-2030)
Table 14: Total Prevalent Cases of Diabetic Gastroparesis in Italy (2017-2030)
Table 15: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy (2017-2030)
Table 16: Prevalence of Diabetic Gastroparesis based on Gender in Italy (2017-2030)
Table 17: Prevalence of Symptoms associated with DGp in Italy (2017-2030)
Table 18: Total Prevalent Cases of Diabetic Gastroparesis in Spain (2017-2030)
Table 19: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain (2017-2030)
Table 20: Prevalence of Diabetic Gastroparesis based on Gender in Spain (2017-2030)
Table 21: Prevalence of Symptoms associated with DGp in Spain (2017-2030)
Table 22: Total Prevalent Cases of Diabetic Gastroparesis in the UK (2017-2030)
Table 23: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK (2017-2030)
Table 24: Prevalence of Diabetic Gastroparesis based on Gender in the UK (2017-2030)
Table 25: Prevalence of Symptoms associated with DGp in the UK (2017-2030)
Table 26: Total Prevalent Cases of Diabetic Gastroparesis in Japan (2017-2030)
Table 27: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan (2017-2030)
Table 28: Prevalence of Diabetic Gastroparesis based on Gender in Japan (2017-2030)
Table 29: Prevalence of Symptoms associated with DGp in Japan (2017-2030)
Table 30: Relamorelin Clinical Trial Description, 2020
Table 31: Metoclopramide Nasal Spray ( Gimoti)Clinical Trial Description, 2020
Table 32: Velusetrag, Clinical Trial Description, 2020
Table 33: CNSA-001, Clinical Trial Description, 2020
Table 34: Velusetrag, Clinical Trial Description, 2020
Table 35: TAK-954, Clinical Trial Description, 2020
Table 36: TAK-906, Clinical Trial Description, 2020
Table 37: Nimacimab, Clinical Trial Description, 2020
Table 38: 7 Major Market Size of Diabetic Gastroparesis in USD Million (2017-2030)
Table 39: 7 Major Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Table 40: United States Market Size of Diabetic Gastroparesis in USD Million (2017-2030)
Table 41: The US Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Table 42: Germany Market Size of Diabetic Gastroparesis in USD Million (2017-2030)
Table 43: Germany Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Table 44: France Market Size of Diabetic Gastroparesis in USD Million (2017-2030)
Table 45: France Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Table 46: Italy Market Size of Diabetic Gastroparesis in USD Million (2017-2030)
Table 47: Italy Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Table 48: Spain Market Size of Diabetic Gastroparesis in USD Million (2017-2030)
Table 49: Spain Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Table 50: United Kingdom Market Size of Diabetic Gastroparesis in USD Million (2017-2030)
Table 51: The UK Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Table 52: Japan Market Size of Diabetic Gastroparesis in USD Million (2017-2030)
Table 53: Japan Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

List of Figures

Figure 1: SWOT Analysis
Figure 2: Glucose and gastric emptying: bidirectional relationship
Figure 3: Pathophysiology of diabetic gastroparesis
Figure 4: Diagnosis algorithm for Diabetic Gastroparesis
Figure 5: Prevalent Patient Population of Diabetic Gastroparesis in 7MM (2017-2030)
Figure 6: Total Prevalent Cases of Diabetic Gastroparesis in the United States (2017-2030)
Figure 7: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the US (2017-2030)
Figure 8: Prevalence of Diabetic Gastroparesis based on Gender in the United States (2017-2030)
Figure 9: Prevalence of Symptoms associated with DGp in the United States (2017-2030)
Figure 10: Total Prevalent Cases of Diabetic Gastroparesis in the Germany (2017-2030)
Figure 11: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany (2017-2030)
Figure 12: Prevalence of Diabetic Gastroparesis based on Gender in Germany (2017-2030)
Figure 13: Prevalence of Symptoms associated with DGp in Germany (2017-2030)
Figure 14: Total Prevalent Cases of Diabetic Gastroparesis in France (2017-2030)
Figure 15: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France (2017-2030)
Figure 16: Prevalence of Diabetic Gastroparesis based on Gender in France (2017-2030)
Figure 17: Prevalence of Symptoms associated with DGp in France (2017-2030)
Figure 18: Total Prevalent Cases of Diabetic Gastroparesis in Italy (2017-2030)
Figure 19: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy (2017-2030)
Figure 20: Prevalence of Diabetic Gastroparesis based on Gender in Italy (2017-2030)
Figure 21: Prevalence of Symptoms associated with DGp in Italy (2017-2030)
Figure 22: Total Prevalent Cases of Diabetic Gastroparesis in Spain (2017-2030)
Figure 23: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain (2017-2030)
Figure 24: Prevalence of Diabetic Gastroparesis based on Gender in Spain (2017-2030)
Figure 25: Prevalence of Symptoms associated with DGp in Spain (2017-2030)
Figure 26: Total Prevalent Cases of Diabetic Gastroparesis in the UK (2017-2030)
Figure 27: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK (2017-2030)
Figure 28: Prevalence of Diabetic Gastroparesis based on Gender in the UK (2017-2030)
Figure 29: Prevalence of Symptoms associated with DGp in the UK (2017-2030)
Figure 30: Total Prevalent Cases of Diabetic Gastroparesis in Japan (2017-2030)
Figure 31: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan (2017-2030)
Figure 32: Prevalence of Diabetic Gastroparesis based on Gender in Japan (2017-2030)
Figure 33: Prevalence of Symptoms associated with DGp in Japan (2017-2030)
Figure 34: Suggested therapeutic options for gastroparesis
Figure 35: Algorithm for the management of diabetic gastroparesis.
Figure 36: Patient Journey for DG
Figure 37: Unmet Needs of Diabetic Gastroparesis
Figure 38: 7 Major Market Size of Diabetic Gastroparesis in USD Million (2017-2030)
Figure 39: 7 Major Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Figure 40: Market Size of Diabetic Gastroparesis in France, USD Million (2017-2030)
Figure 41: The US Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Figure 42: Market Size of Diabetic Gastroparesis in Germany, USD Million (2017-2030)
Figure 43: Germany Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Figure 44: Market Size of Diabetic Gastroparesis in France USD Million (2017-2030)
Figure 45: France Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Figure 46: Market Size of Diabetic Gastroparesis in Italy, USD Million (2017-2030)
Figure 47: Italy Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Figure 48: Market Size of Diabetic Gastroparesis in Spain, USD Million (2017-2030)
Figure 49: Spain Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Figure 50: Market Size of Diabetic Gastroparesis in the United Kingdom, USD Million (2017-2030)
Figure 51: The UK Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Figure 52: Market Size of Diabetic Gastroparesis in Japan, USD Million (2017-2030)
Figure 53: Japan Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)
Figure 54: Market Drivers
Figure 55: Market Barriers
  • Global Anti-Peptic Ulcer Drugs Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 110
    According to our LPI (LP Information) latest study, the global Anti-Peptic Ulcer Drugs market size was valued at US$ 8523.5 million in 2023. With growing demand in downstream market, the Anti-Peptic Ulcer Drugs is forecast to a readjusted size of US$ 21200 million by 2030 with a CAGR of 13.9% during review period. The research report highlights the growth potential of the global Anti-Peptic Ulcer Drugs market. Anti-Peptic Ulcer Drugs are expected to show stable growth in the future marke......
  • Global Lansoprazole Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 102
    The Lansoprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lansoprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the comp......
  • Global Irritable Bowel Syndrome (IBS) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 88
    According to our LPI (LP Information) latest study, the global Irritable Bowel Syndrome (IBS) market size was valued at US$ 4634.2 million in 2023. With growing demand in downstream market, the Irritable Bowel Syndrome (IBS) is forecast to a readjusted size of US$ 12750 million by 2030 with a CAGR of 15.6% during review period. The research report highlights the growth potential of the global Irritable Bowel Syndrome (IBS) market. Irritable Bowel Syndrome (IBS) are expected to show stabl......
  • Global Esomeprazole Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 89
    The Esomeprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Esomeprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the comp......
  • Global Irritable Bowel Syndrome (IBS) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 126
    Market Overview of Global Irritable Bowel Syndrome (IBS) market: According to our latest research, the global Irritable Bowel Syndrome (IBS) market looks promising in the next 5 years. As of 2022, the global Irritable Bowel Syndrome (IBS) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive anal......
  • Global Diarrhea Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 109
    Market Overview of Global Diarrhea Drug market: According to our latest research, the global Diarrhea Drug market looks promising in the next 5 years. As of 2022, the global Diarrhea Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Diarrhea Drug market, with a sys......
  • Drugs for Traveler's Diarrhea - Global Market Insights and Sales Trends 2024
    Published: 27-Dec-2023        Price: US 3350 Onwards        Pages: 96
    This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Drugs for Traveler's Diarrhea, with bo......
  • Global Lansoprazole Professional Survey Report 2023, Forecast to 2028
    Published: 26-Dec-2023        Price: US 3280 Onwards        Pages: 136
    Lansoprazole reduces the amount of acid your stomach makes. It's used for indigestion, heartburn and acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is also taken to prevent and treat stomach ulcers. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their g......
  • Global Pentasa (Ulcerative Colitis) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 113
    Market Overview of Global Pentasa (Ulcerative Colitis) market: According to our latest research, the global Pentasa (Ulcerative Colitis) market looks promising in the next 5 years. As of 2022, the global Pentasa (Ulcerative Colitis) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis o......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs